Physician profile
Constance J Alexander
NPI 1760493977
$19,638.15
in general payments reported to CMS, 2019-2025
43 companies · $2,696 in 2025
The $2,696 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,111 · 2020: $2,363 · 2021: $3,601 · 2022: $3,469 · 2023: $3,392 · 2024: $2,007 · 2025: $2,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,591 · Debt Forgiveness: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,591.02 |
| Debt Forgiveness | $503.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,890.66 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $1,996.57 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Alkermes, INC. | $1,631.76 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $1,590.98 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $1,339.71 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $1,285.96 | 2019-2023 | Trintellix |
| Lundbeck LLC | $1,188.69 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $981.00 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $701.84 | 2022-2025 | Auvelity, Sunosi, Symbravo |
| Vanda Pharmaceuticals INC. | $649.27 | 2019-2025 | Fanapt, Hetlioz |
| Neuronetics, INC. | $610.44 | 2019-2025 | Neurostar Tms Therapy System |
| Neurocrine Biosciences, INC. | $454.25 | 2019-2025 | Ingrezza |
| Allergan, INC. | $414.05 | 2019-2020 | |
| Harmony Biosciences LLC | $404.27 | 2020-2025 | Wakix |
| Teva Pharmaceuticals USA, INC. | $374.39 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $338.85 | 2022-2024 | Qelbree, Qelbree |
| Bausch Health US, LLC | $276.96 | 2019-2025 | Aplenzin |
| Corium, LLC | $256.01 | 2022-2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $200.76 | 2020-2022 | |
| Eisai INC. | $200.72 | 2020-2022 | |
| Indivior INC. | $178.92 | 2019-2025 | Sublocade |
| Merck Sharp & Dohme LLC | $168.80 | 2019-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $144.23 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $140.15 | 2023-2025 | Quviviq, Quviviq |
| E.R. Squibb & Sons, L.L.C. | $128.60 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $123.45 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Adlon Therapeutics L.P. | $114.38 | 2020-2021 | |
| Noven Therapeutics, LLC | $112.96 | 2024-2025 | Xelstrym, Secuado |
| Neos Therapeutics, LP | $108.80 | 2020-2024 | Adzenys Xr-Odt |
| Shire North American Group INC | $96.55 | 2019 | |
| Tris Pharma INC | $86.44 | 2022-2025 | Dyanavel Xr |
| Titan Pharmaceuticals, INC. | $77.07 | 2020 | |
| Braeburn INC. | $76.87 | 2024-2025 | Brixadi |
| Ironshore Pharmaceuticals INC. | $67.88 | 2022-2023 | Jornay Pm |
| Pfizer INC. | $65.10 | 2025 | |
| Orexo US, INC. | $30.95 | 2021 | |
| Arbor Pharmaceuticals, INC. | $28.57 | 2019 | |
| Alfasigma USA, INC. | $27.16 | 2021 | |
| Owp Pharmaceuticals, INC. | $17.91 | 2020 | |
| Collegium Pharmaceutical, INC. | $15.37 | 2025 | Jornay Pm |
| Sumitomo Pharma America, INC. | $14.74 | 2023 | Latuda |
| Kaleo, INC. | $13.86 | 2019 | |
| Hikma Pharmaceuticals USA | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.